Article
Multidisciplinary Sciences
Yotaro Ochi, Kenichi Yoshida, Ying-Jung Huang, Ming-Chung Kuo, Yasuhito Nannya, Ko Sasaki, Kinuko Mitani, Noriko Hosoya, Nobuhiro Hiramoto, Takayuki Ishikawa, Susan Branford, Naranie Shanmuganathan, Kazuma Ohyashiki, Naoto Takahashi, Tomoiku Takaku, Shun Tsuchiya, Nobuhiro Kanemura, Nobuhiko Nakamura, Yasunori Ueda, Satoshi Yoshihara, Rabindranath Bera, Yusuke Shiozawa, Lanying Zhao, June Takeda, Yosaku Watatani, Rurika Okuda, Hideki Makishima, Yuichi Shiraishi, Kenichi Chiba, Hiroko Tanaka, Masashi Sanada, Akifumi Takaori-Kondo, Satoru Miyano, Seishi Ogawa, Lee-Yung Shih
Summary: In chronic myeloid leukaemia (CML), the drivers of blast crisis and resistance to tyrosine kinase inhibitors are not fully characterised. Analysis of a cohort of CML samples using genomic technologies reveals that at least one driver alteration is associated with progression and worse prognosis. Genetic abnormalities can help predict clinical outcomes and guide clinical decisions in CML.
NATURE COMMUNICATIONS
(2021)
Article
Biochemistry & Molecular Biology
Dragoslava Dikic, Andrija Bogdanovic, Dragana Markovic, Olivera Mitrovic-Ajtic, Tijana Suboticki, Milos Diklic, Milica Vukotic, Teodora Dragojevic, Emilija Zivkovic, Juan F. Santibanez, Vladan P. Cokic
Summary: This study analyzed the relationship between oxidative stress and inflammatory factors in chronic myelogenous leukemia (CML). The results showed increased oxidative stress markers, decreased antioxidant enzyme activity, increased inflammation markers, and decreased anti-inflammatory cytokine levels in CML patients. The study also found enhanced activity of the AKT/mTOR signaling pathway, suggesting that chronic inflammation is involved in the development of CML.
Article
Pathology
Zelin Zhang, Xianqi Huang, Qi Yan, Yani Lin, Enbin Liu, Yingchang Mi, Shi Liang, Hao Wang, Jun Xu, Kun Ru
Summary: In this study, a model called CMLcGAN was developed for segmenting bone marrow cells, which achieved better performance compared to other segmentation models. By extracting statistical features and conducting clinical validation, the model demonstrated good accuracy in clinical prediction.
AMERICAN JOURNAL OF PATHOLOGY
(2022)
Article
Hematology
Hagop M. Kantarjian, Elias Jabbour, Michael Deininger, Elisabetta Abruzzese, Jane Apperley, Jorge Cortes, Charles Chuah, Daniel J. DeAngelo, John DiPersio, Andreas Hochhaus, Jeffrey Lipton, Franck E. Nicolini, Javier Pinilla-Ibarz, Delphine Rea, Gianantonio Rosti, Philippe Rousselot, Neil P. Shah, Moshe Talpaz, Shouryadeep Srivastava, Xiaowei Ren, Michael Mauro
Summary: Ponatinib has demonstrated deep and durable responses in patients with chronic-phase chronic myeloid leukemia, especially in those resistant to second-generation TKI treatment, and has shown good safety and survival outcomes.
AMERICAN JOURNAL OF HEMATOLOGY
(2022)
Article
Multidisciplinary Sciences
Golnaz Ensieh Kazemi-Sefat, Mohammad Keramatipour, Mohammad Vaezi, Seyed Mohsen Razavi, Kaveh Kavousi, Amin Talebi, Shahrbanoo Rostami, Marjan Yaghmaei, Bahram Chahardouli, Saeed Talebi, Kazem Mousavizadeh
Summary: This study identified important genetic variants in patients with myeloid blast crisis chronic myeloid leukemia (CML) using integrated genomic sequencing. These variants affect genes involved in leukemia stem cell proliferation, self-renewal, and differentiation. RNA sequencing was used to confirm these variants. This approach provides insights into the pathophysiology of CML and may aid in its management.
SCIENTIFIC REPORTS
(2022)
Article
Biochemistry & Molecular Biology
Daniel Cacic, Oddmund Nordgard, Peter Meyer, Tor Hervig
Summary: In this study, platelet microparticles (PMPs) were found to protect AML cells against apoptosis by transferring bioactive molecules to cancer cells and downregulating the pro-apoptotic PUMA protein, thereby reducing DNA damage induced by chemotherapeutic agents. These findings suggest a potential role for PMPs in modulating apoptosis in AML cells.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Pharmacology & Pharmacy
Hyacinthe Johnson-Ansah, Benjamin Maneglier, Francoise Huguet, Laurence Legros, Martine Escoffre-Barbe, Martine Gardembas, Pascale Cony-Makhoul, Valerie Coiteux, Laurent Sutton, Wajed Abarah, Camille Pouaty, Jean-Michel Pignon, Bachra Choufi, Sorin Visanica, Benedicte Deau, Laure Morisset, Emilie Cayssials, Mathieu Molimard, Stephane Bouchet, Francois-Xavier Mahon, Franck Nicolini, Philippe Aegerter, Jean-Michel Cayuela, Marc Delord, Heriberto Bruzzoni-Giovanelli, Philippe Rousselot
Summary: This study evaluated the value of therapeutic drug monitoring (TDM) in imatinib treatment for patients with chronic myelogenous leukemia. The results showed that TDM strategy significantly increased the plasma concentration of imatinib and improved the treatment outcome for patients.
Review
Oncology
Maiko Matsushita
Summary: Although TKIs are effective in treating CML patients, LSCs are resistant to them. Immunotherapies targeting LSCs may be crucial in curing CML.
Article
Medicine, General & Internal
Wei Wang, Ya-Ling Chen, Pan-Pan Gou, Pei-Lin Wu, Kun-Sheng Shan, Dong-Liang Zhang
Summary: This study reports a rare case of lymphoblastic transformation to erythroid leukemia in a patient with CML and discusses its mechanism.
WORLD JOURNAL OF CLINICAL CASES
(2023)
Article
Chemistry, Medicinal
Futoon Abedrabbu Al-Rawashde, Ola M. Al-Sanabra, Moath Alqaraleh, Ahmad Q. Jaradat, Abdullah Saleh Al-Wajeeh, Muhammad Farid Johan, Wan Rohani Wan Taib, Imilia Ismail, Hamid Ali Nagi Al-Jamal
Summary: The aim of this study is to assess the ability of TQ to enhance the expression of SHP-1 through modifying DNA methylation in K562 CML cells. TQ downregulated the DNMT1 gene, DNMT3A gene, and DNMT3B gene, and upregulated the WT1 gene and TET2 gene, leading to hypomethylation and restoration of SHP-1 expression. This resulted in inhibition of JAK/STAT signaling, induction of apoptosis, and cell cycle arrest.
Article
Biochemistry & Molecular Biology
Kristan V. Piroeva, Charlotte Mcdonald, Charalampos Xanthopoulos, Chelsea Fox, Christopher T. Clarkson, Jan-Philipp Mallm, Yevhen Vainshtein, Luminita Ruje, Lara C. Klett, Stephan Stilgenbauer, Daniel Mertens, Efterpi Kostareli, Karsten Rippe, Vladimir B. Teif
Summary: This study compared the nucleosome positions in chronic lymphocytic leukemia (CLL) patients and healthy individuals, and found significant changes in nucleosome positioning in CLL. The spacing between nucleosomes was shortened, and changes in nucleosome occupancy were linked to chromatin remodeling and reduced DNA methylation. Nucleosome positioning can be used to classify CLL subtypes and monitor disease progression.
Review
Cell Biology
Fang Hao, Chen Wang, Christine Sholy, Min Cao, Xunlei Kang
Summary: Protein tyrosine phosphatases play a crucial role in modulating cellular functions and have been linked to human leukemia; however, the impact of these phosphatases and their mutations on leukemia remains controversial.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Virology
Priya Devi, Katarina Engdahl, Tanel Punga, Anders Bergqvist
Summary: HCV C protein is associated with the CpG methylation profile at SHP-1 P2, and NGS-BS is a sensitive method for characterizing CpG methylation status and cis-acting effects on epigenetic regulation.
Article
Hematology
Jorge Cortes, Jane Apperley, Elza Lomaia, Beatriz Moiraghi, Maria Undurraga Sutton, Carolina Pavlovsky, Charles Chuah, Tomasz Sacha, Jeffrey H. Lipton, Charles A. Schiffer, James McCloskey, Andreas Hochhaus, Philippe Rousselot, Gianantonio Rosti, Hugues de Lavallade, Anna Turkina, Christine Rojas, Christopher Kevin Arthur, Lori Maness, Moshe Talpaz, Michael Mauro, Tracey Hall, Vickie Lu, Shouryadeep Srivastava, Michael Deininger
Summary: The study focused on the treatment of CP-CML patients with different doses of ponatinib, finding that the optimal benefit/risk outcomes were achieved with a starting dose of 45 mg and decreased to 15 mg upon response.
Article
Hematology
Aram Bidikian, Elias Jabbour, Ghayas C. C. Issa, Nicholas J. J. Short, Koji Sasaki, Hagop Kantarjian
Summary: Achieving major molecular response (MMR) with BCR::ABL1 tyrosine kinase inhibitors (TKIs) is important in the treatment of chronic myeloid leukemia (CML). However, patients who achieve a major cytogenetic response (MCyR) within the first 2 years of TKI therapy can still have good long-term outcomes, even without achieving MMR. The value of MMR is less pronounced among older CML patients, who often face mortality due to comorbidities unrelated to CML.
AMERICAN JOURNAL OF HEMATOLOGY
(2023)